查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1371955

2030 年生物標記市場預測：按產品類型、適應症、服務、用途、最終用戶和地區進行的全球分析

Biomarker Market Forecasts to 2030 - Global Analysis By Product (Consumables, Software and Services), Type (Safety Biomarkers, Validation Biomarkers and Efficacy Biomarkers), Indication, Service, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球生物標記市場規模為 581.2 億美元，預計到 2030 年將達到 1,102.4 億美元，預測期內年複合成長率為 14.2%。

生物標記是生物標記的簡稱，指檢測、可量化的生物參數或特徵，是生理或病理過程、疾病狀態或治療反應的指標。生物標記存在於多種生物樣本中，包括血液、尿液、組織和其他體液。生物標記包括廣泛的屬性，包括遺傳變異、基因表現模式、蛋白質水平、酶活性、代謝物濃度和影像特徵。

根據中國衛生署公佈的資料，約有2.03億人患有心血管疾病，預計2030年這數字將增加73%。

癌症罹患率增加

癌症是一種複雜的疾病，由階段致癌過程引起，涉及多個分子途徑事件，使診斷、預後和治療變得困難。癌症很複雜，因此沒有單一的標記物是有效的。此外，不同類型的癌症具有不同的分子特徵。新型生物標記的鑒定為開發旨在糾正癌症失調的治療方法開闢了新途徑。因此，由於生物標記研究的開拓和癌症罹患率的上升，全球市場預計將擴大。

嚴格法規

生物標記市場實行嚴格的規則和法規，以在醫療保健提供者、患者和相關人員之間建立信任和信心。這對於廣泛採用基於生物標記的診斷和治療至關重要。法規促進了生物標記開發、檢驗和應用的標準化。這些法規的複雜性使得它們對於做出資訊的醫療決策至關重要。因此，這個因素阻礙了市場的成長。

個人化醫療日益普及

個人化醫療依賴於識別患者疾病的特定遺傳、分子和生化特徵的生物標記。這些生物標記有助於確定最有效的治療方法並最大限度地減少試驗的需要。個人化醫療旨在透過根據每位患者的生物體質制定治療方案來提高治療效果。以生物標記為指導的個人個人化醫療可以根據患者的個別特徵客製化藥物給藥和治療方法，從而最佳化治療結果。它透過提高患者參與度和滿意度來推動市場成長，從而實現早期疾病檢測和預防。

開發成本高

生物標記的開發需要大量資金和涉及科學家、臨床醫生、法規專家和其他專家的多學科方法。高開發成本反映了將可靠的生物標記物引入臨床所需的複雜性和嚴格性。此外，生物標記的開發通常涉及一個漫長的迭代過程。此外，維持高品質品質、僱用熟練的科學家和建造技術基礎設施都會產生額外的成本，從而阻礙市場需求。

COVID-19 的影響

COVID-19 大流行將對生物標記物產業產生適度的正面影響，因為生物標記物對於為 COVID-19 患者創造治療方法至關重要。許多研究發現生物標記對於診斷和治療至關重要。此外，一些組織還宣布了用於鑒定和治療 COVID-19 的生物標記產品。這些新興市場的開拓使得市場在疫情期間不斷擴大。

腫瘤學領域預計在預測期內規模最大

癌症領域預計將出現良好的成長。生物標記在癌症診斷、預後和治療中發揮重要作用。生物標記是檢測的生物指標，可以提供有關癌症的存在、進展以及對某些治療的反應性的資訊。它有助於鑒定腫瘤的特定分子或遺傳特徵，從而可以選擇更有效的標靶治療。從早期檢測到治療方法選擇、監測和監測，生物標記有助於為癌症診斷和治療提供更個體化和有效的方法。

診斷與研究實驗室部門預計在預測期內年複合成長率最高

診斷與研究實驗室領域預計在預測期內將以最高的年複合成長率成長。診斷實驗室在監測疾病進展和評估治療效果方面發揮重要作用。診斷和研究實驗室在生物標記領域的進步中發揮著至關重要的作用。我們參與生物標記開發和應用過程的每階段，從生物標記發現和檢驗到臨床試驗、檢測開發和患者照護。他們的工作對診斷疾病、選擇治療方法和改善患者的治療效果做出了重大貢獻。

比最大的地區

由於高疾病負擔、消費者對生物標記的認知不斷提高、政府配合措施、技術突破和醫療保健基礎設施的改善，預計北美在預測期內將佔據最大的市場佔有率。事實確實如此。在北美，美國佔有最大的市場佔有率。預計推動該地區成長的關鍵因素是該領域知名公司的存在以及他們正在進行的許多有機和無機項目。

複合年複合成長率最高的地區：

由於癌症罹患率、研究計畫不斷增加和臨床試驗成本低，預計亞太地區在預測期內將呈現最高的年複合成長率。生物標記在藥物研發和藥物開發過程中的應用正在推動新生物標記開發的研究投資。此外，對生物技術和製藥公司的資助增加、合約研究組織數量的增加以及生物標記應用範圍的擴大預計將在預測期內推動區域市場的成長。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球生物標記市場：依產品

  • 消耗品
  • 軟體
  • 服務

第6章 全球生物標記市場：依類型

  • 安全生物標記
  • 檢驗生物標記
  • 功效生物標記
    • 預測性生物標記
    • 替代生物標記
    • 動態生物標記
    • 預後生物標記

第7章 全球生物標記市場：依適應症分類

  • 癌症
  • 心血管疾病
  • 感染疾病
  • 神經系統疾病
  • 免疫疾病
  • 其他適應症

第8章 全球生物標記市場：依服務分類

  • 檢測開發
  • 生物標記檢驗和測試
  • 樣品製備
  • 其他服務

第9章 全球生物標記市場：依用途

  • 藥物研發發現與開發
  • 疾病診斷
    • 腫瘤學
    • 神經病學
    • 心臟病學
  • DNA指紋分析
  • 個人化醫療
  • 疾病風險評估
  • 其他用途

第10章 全球生物標記市場：依最終用戶分類

  • 製藥和生物技術公司
  • 醫院和專科診所
  • 診斷和研究機構
  • 其他最終用戶

第11章全球生物標誌市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第12章進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章公司簡介

  • GE Healthcare
  • Aushon Biosystem
  • Eisai Co. Limited
  • Abbott Laboratories, Inc.
  • Epistem Limited
  • Agilent Technologies Inc.
  • Roche Diagnostics Limited
  • Siemens AG
  • Bio-Rad Laboratories
  • Thermo Fisher Scientific Inc.
  • Johnson & Johnson Services, Inc.
  • Epigenomics AG
  • QIAGEN
  • Enzo Biochem Inc
  • Charles River Laboratories International Inc.
  • Eurofins Scientific
  • LifeSign LLC
  • Bruker
  • Sino Biological Inc
  • Quest Diagnostics Incorporated
Product Code: SMRC24012

According to Stratistics MRC, the Global Biomarker Market is accounted for $58.12 billion in 2023 and is expected to reach $110.24 billion by 2030 growing at a CAGR of 14.2% during the forecast period. A biomarker, short for biological marker, refers to a measurable and quantifiable biological parameter or characteristic that serves as an indicator of a physiological or pathological process, a disease state, or a response to treatment. Biomarkers can be found in various biological samples, such as blood, urine, tissue, or other bodily fluids. Biomarkers can encompass a wide range of attributes, including genetic mutations, gene expression patterns, protein levels, enzyme activity, metabolite concentrations, and imaging features.

According to data published by ministry of health in China, about 203 million people are suffering from cardiovascular diseases and this number is expected to increase by 73% in 2030.

Market Dynamics:

Driver:

Increase in cancer incidence

Cancer is a complicated illness caused by a multi-stage carcinogenesis process with several molecular pathway events that make diagnosis, prognosis, and treatment difficult. A single marker is ineffective because cancer is complicated. Additionally, each kind of cancer has a unique molecular profile from the others. The identification of novel biomarkers opens up new avenues for the development of treatment approaches intended to correct dysregulation in cancer. As a result, the worldwide market will expand due to the development of biomarker research and the rising incidence of cancer.

Restraint:

Strict regulations

Strict rules and regulations are imposed to help build confidence and trust among healthcare providers, patients, and stakeholders in the biomarker market. This is crucial for the widespread adoption of biomarker-based diagnostics and therapies. Regulations promote standardization in the development, validation, and application of biomarkers. These regulations are complex and therefore become critical for making uninformed medical decisions. Thereby, this element hampers the market growth.

Opportunity:

Rising popularity of personalized medicine

Personalized medicine relies on biomarkers to identify specific genetic, molecular, or biochemical characteristics of a patient's disease. These biomarkers help determine the most effective treatment options, minimizing the need for trial-and-error approaches. By tailoring treatments to the individual patient's biological makeup, personalized medicine aims to increase treatment efficacy. Personalized medicine, guided by biomarkers, allows for the customization of drug dosage and treatment regimens based on individual patient characteristics, optimizing therapeutic outcomes. Its greater patient engagement and satisfaction followed up by early disease detection and prevention fuels the market growth.

Threat:

High development costs

The development of biomarkers requires significant financial investment and a multidisciplinary approach involving scientists, clinicians, regulatory experts, and other professionals. The high development costs reflect the complexity and rigor required to bring reliable biomarkers to clinical practice. Also, biomarker development often involves long and iterative processes; this prolonged timeline can result in cumulative costs. In addition, maintaining high standards of quality, recruiting skilled scientists and setting up technological infrastructure adds extra expenses which hinder the market demand.

COVID-19 Impact

The COVID-19 pandemic has a moderately beneficial effect on the biomarkers industry since biomarkers are essential for the creation of COVID-19 patient therapeutics. Biomarkers were discovered to be essential in the diagnosis and therapy in a number of studies. In addition, several organisations have introduced biomarker products to identify and treat COVID-19. These developments caused the market to expand throughout the pandemic era.

The cancer segment is expected to be the largest during the forecast period

The cancer segment is estimated to have a lucrative growth. Biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They are measurable biological indicators that can provide information about the presence or progression of cancer, as well as the likely response to specific treatments. It can help identify specific molecular or genetic characteristics of a tumor, allowing for the selection of targeted therapies that are more likely to be effective. From early detection to treatment selection, monitoring and research, biomarker contributes to more personalized and effective approaches to cancer diagnosis and treatment.

The diagnostics & research laboratories segment is expected to have the highest CAGR during the forecast period

The diagnostics & research laboratories segment is anticipated to witness the highest CAGR growth during the forecast period. Diagnostic labs play a vital role in monitoring disease progression and evaluating the effectiveness of treatments. Diagnostics and research laboratories play a pivotal role in advancing the field of biomarkers. They are involved in every stage of the biomarker development and application process, from discovery and validation to clinical testing, assay development, and patient care. Their work contributes significantly to improving disease diagnosis, treatment selection, and patient outcomes.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the high disease burden, rising consumer awareness of biomarkers, encouraging government efforts, technical breakthroughs, and improvements in healthcare infrastructure. In North America, the United States holds the largest market share. A significant element anticipated to fuel the region's growth is the presence of prominent firms in this area and the many organic and inorganic projects they have undertaken.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to its high prevalence of cancer, rising research initiatives, and low cost of clinical trials. Application of biomarkers in the drug discovery and development process is boosting key market players to invest in the research to develop novel biomarkers. In addition, an increase in funding for biotech and pharma companies, a rise in the number of CROs, and an increasing application scope of biomarkers are expected to facilitate regional market growth during the projected period.

Key players in the market:

Some of the key players profiled in the Biomarker Market include: GE Healthcare, Aushon Biosystem, Eisai Co. Limited, Abbott Laboratories, Inc., Epistem Limited, Agilent Technologies Inc., Roche Diagnostics Limited, Siemens AG, Bio-Rad Laboratories, Thermo Fisher Scientific Inc., Johnson & Johnson Services, Inc., Epigenomics AG, QIAGEN, Enzo Biochem Inc, Charles River Laboratories International Inc., Eurofins Scientific, LifeSign LLC, Bruker, Sino Biological Inc and Quest Diagnostics Incorporated.

Key Developments:

In November 2022, Siemens is expanding its generator circuit-breaker portfolio with a new compact version - the HB1-Compact (HB1-C). The versatile and highly customizable solution uses maintenance-free vacuum switching technology and addresses the most challenging of constraints.

In September 2022, GE Healthcare, a medical technology, diagnostics, and digital solutions company, launched its 'Made in India', 'AI-powered' Cath lab-Optima IGS 320 to advance cardiac care in India. It is built at Wipro GE Healthcare's new Bengaluru factory and leverages the GE proprietary AutoRight technology.

Products Covered:

  • Consumables
  • Software
  • Services

Types Covered:

  • Safety Biomarkers
  • Validation Biomarkers
  • Efficacy Biomarkers

Indications Covered:

  • Cancer
  • Cardiovascular Disorders
  • Infectious Diseases
  • Neurological Disorders
  • Immunological Disorders
  • Other Indications

Services Covered:

  • Assay Development
  • Biomarker Validation & Testing
  • Sample Preparation
  • Other Services

Applications Covered:

  • Drug Discovery & Development
  • Disease Diagnostics
  • DNA Fingerprinting
  • Personalized Medicine
  • Disease Risk Assessment
  • Other Applications

End Users Covered:

  • Pharmaceutical & Biotechnology Companies
  • Hospitals & Specialty Clinics
  • Diagnostics & Research Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Biomarker Market, By Product

  • 5.1 Introduction
  • 5.2 Consumables
  • 5.3 Software
  • 5.4 Services

6 Global Biomarker Market, By Type

  • 6.1 Introduction
  • 6.2 Safety Biomarkers
  • 6.3 Validation Biomarkers
  • 6.4 Efficacy Biomarkers
    • 6.4.1 Predictive Biomarkers
    • 6.4.2 Surrogate Biomarkers
    • 6.4.3 Pharmacodynamic Biomarkers
    • 6.4.4 Prognostic Biomarkers

7 Global Biomarker Market, By Indication

  • 7.1 Introduction
  • 7.2 Cancer
  • 7.3 Cardiovascular Disorders
  • 7.4 Infectious Diseases
  • 7.5 Neurological Disorders
  • 7.6 Immunological Disorders
  • 7.7 Other Indications

8 Global Biomarker Market, By Service

  • 8.1 Introduction
  • 8.2 Assay Development
  • 8.3 Biomarker Validation & Testing
  • 8.4 Sample Preparation
  • 8.5 Other Services

9 Global Biomarker Market, By Application

  • 9.1 Introduction
  • 9.2 Drug Discovery & Development
  • 9.3 Disease Diagnostics
    • 9.3.1 Oncology
    • 9.3.2 Neurology
    • 9.3.3 Cardiology
  • 9.4 DNA Fingerprinting
  • 9.5 Personalized Medicine
  • 9.6 Disease Risk Assessment
  • 9.7 Other Applications

10 Global Biomarker Market, By End User

  • 10.1 Introduction
  • 10.2 Pharmaceutical & Biotechnology Companies
  • 10.3 Hospitals & Specialty Clinics
  • 10.4 Diagnostics & Research Laboratories
  • 10.5 Other End Users

11 Global Biomarker Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 GE Healthcare
  • 13.2 Aushon Biosystem
  • 13.3 Eisai Co. Limited
  • 13.4 Abbott Laboratories, Inc.
  • 13.5 Epistem Limited
  • 13.6 Agilent Technologies Inc.
  • 13.7 Roche Diagnostics Limited
  • 13.8 Siemens AG
  • 13.9 Bio-Rad Laboratories
  • 13.10 Thermo Fisher Scientific Inc.
  • 13.11 Johnson & Johnson Services, Inc.
  • 13.12 Epigenomics AG
  • 13.13 QIAGEN
  • 13.14 Enzo Biochem Inc
  • 13.15 Charles River Laboratories International Inc.
  • 13.16 Eurofins Scientific
  • 13.17 LifeSign LLC
  • 13.18 Bruker
  • 13.19 Sino Biological Inc
  • 13.20 Quest Diagnostics Incorporated

List of Tables

  • Table 1 Global Biomarker Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Biomarker Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Biomarker Market Outlook, By Safety Biomarkers (2021-2030) ($MN)
  • Table 4 Global Biomarker Market Outlook, By Validation Biomarkers (2021-2030) ($MN)
  • Table 5 Global Biomarker Market Outlook, By Efficacy Biomarkers (2021-2030) ($MN)
  • Table 6 Global Biomarker Market Outlook, By Predictive Biomarkers (2021-2030) ($MN)
  • Table 7 Global Biomarker Market Outlook, By Surrogate Biomarkers (2021-2030) ($MN)
  • Table 8 Global Biomarker Market Outlook, By Pharmacodynamic Biomarkers (2021-2030) ($MN)
  • Table 9 Global Biomarker Market Outlook, By Prognostic Biomarkers (2021-2030) ($MN)
  • Table 10 Global Biomarker Market Outlook, By Indication (2021-2030) ($MN)
  • Table 11 Global Biomarker Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 12 Global Biomarker Market Outlook, By Cardiovascular Disorders (2021-2030) ($MN)
  • Table 13 Global Biomarker Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 14 Global Biomarker Market Outlook, By Neurological Disorders (2021-2030) ($MN)
  • Table 15 Global Biomarker Market Outlook, By Immunological Disorders (2021-2030) ($MN)
  • Table 16 Global Biomarker Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 17 Global Biomarker Market Outlook, By Service (2021-2030) ($MN)
  • Table 18 Global Biomarker Market Outlook, By Assay Development (2021-2030) ($MN)
  • Table 19 Global Biomarker Market Outlook, By Biomarker Validation & Testing (2021-2030) ($MN)
  • Table 20 Global Biomarker Market Outlook, By Sample Preparation (2021-2030) ($MN)
  • Table 21 Global Biomarker Market Outlook, By Other Services (2021-2030) ($MN)
  • Table 22 Global Biomarker Market Outlook, By Application (2021-2030) ($MN)
  • Table 23 Global Biomarker Market Outlook, By Drug Discovery & Development (2021-2030) ($MN)
  • Table 24 Global Biomarker Market Outlook, By Disease Diagnostics (2021-2030) ($MN)
  • Table 25 Global Biomarker Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 26 Global Biomarker Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 27 Global Biomarker Market Outlook, By Cardiology (2021-2030) ($MN)
  • Table 28 Global Biomarker Market Outlook, By DNA Fingerprinting (2021-2030) ($MN)
  • Table 29 Global Biomarker Market Outlook, By Personalized Medicine (2021-2030) ($MN)
  • Table 30 Global Biomarker Market Outlook, By Disease Risk Assessment (2021-2030) ($MN)
  • Table 31 Global Biomarker Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 32 Global Biomarker Market Outlook, By End User (2021-2030) ($MN)
  • Table 33 Global Biomarker Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
  • Table 34 Global Biomarker Market Outlook, By Hospitals & Specialty Clinics (2021-2030) ($MN)
  • Table 35 Global Biomarker Market Outlook, By Diagnostics & Research Laboratories (2021-2030) ($MN)
  • Table 36 Global Biomarker Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.